EVALUATION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXPRESSION IN UROTHELIAL CARCINOMA: A POSSIBLE PROGNOSTIC ROLE

Authors

  • Shifa Basharat Department of Histopathology, Rehman Medical Institute, Hayatabad, Peshawar-Pakistan
  • Ayesha Sajjad Department of Histopathology, Rehman Medical Institute, Hayatabad, Peshawar-Pakistan
  • Faryal Javaid Department of Histopathology, Rehman Medical Institute, Hayatabad, Peshawar-Pakistan
  • Maria Khan Department of Pathology, Pakistan Institute of Cardiology, Peshawar-Pakistan
  • Maria Tasneem Khattak Department of Histopathology, Rehman Medical Institute, Hayatabad, Peshawar-Pakistan
  • Iqbal Muhammad Khan Department of Histopathology, Rehman Medical Institute, Hayatabad, Peshawar-Pakistan

DOI:

https://doi.org/10.55519/JAMC-02-12584

Keywords:

Urothelial Carcinoma, EGFR, Bladder Cancer, Epidermal Growth Factor Receptor

Abstract

Background: Urothelial carcinoma is a subtype of urinary bladder cancer which carries a higher morbidity and mortality worldwide. It is estimated that 90% of the patients presenting to the hospitals with history of bladder cancer are diagnosed with urothelial carcinomas. Objective of the study was to evaluate the strength of EGFR expression and its prognostic role in urothelial carcinoma. It was a cross-sectional study conducted at the Rehman Medical Institute Peshawar from July 2022 to February 2023. Methods: A total of 98 specimens of patients diagnosed with urothelial carcinoma were examined in histopathology department. Patients with other malignancies were excluded. Demographic characteristics of participants, tumour grading, invasion of the surrounding structures and EGFR expression was recorded, and data analysis was performed with SPSS-23. Results:  Mean age of the participants was 58.68±8.61 years. Gender distribution revealed 67(68.4%) males and 31(31.6%) females with a male to female ratio of 2.1:1. A total of 61 (62.2%) patients exhibited low grade of urothelial carcinoma while 37(37.8%) patients showed high grade malignancy. Expression of EGFR was not observed in 04 (4.1%) specimens while 62(63.3%) specimens revealed weak to moderate expression and 32(32.7%) showed strong expression of EGFR. Out of 61 patients with low grade of tumour, 04 (6.6%) patients exhibited no expression, 50(80%) patients exhibited weak to moderate expression and 07(11.5%) patients revealed strong expression of EGFR. Out of 37 patients with high tumour grade, 12(32.4%) revealed weak to moderate and 25 (67.6%) revealed strong expression of EGFR. Higher tumour grades and tumours with deeper penetration revealed a strong expression of EGFR with a p-value of <0.001. Conclusion: Strong expression of EGFR in tumours with higher grade validates its prognostic role and can be utilized for targeted therapy with potentially lifesaving consequences in patients presenting with urothelial carcinoma.

References

Mollica V, Rizzo A, Montironi R, Cheng L, Giunchi F, Schiavina R et al. Current strategies and novel therapeutic approaches for metastatic urothelial carcinoma. Cancers. 2020 Jun 2;12(6):1449.

Minoli M, Kiener M, Thalmann GN, Kruithof-de Julio M, Seiler R. Evolution of urothelial bladder cancer in the context of molecular classifications. International journal of molecular sciences. 2020 Aug 7;21(16):5670.

Wu J, Chen S, Wu X, Mao W, Wang Y, Xu B, Zheng D, Chen M. Trends of incidence and prognosis of upper tract urothelial carcinoma. Bosnian journal of basic medical sciences. 2021 Oct;21(5):607.

Thompson DB, Siref LE, Feloney MP, Hauke RJ, Agrawal DK. Immunological basis in the pathogenesis and treatment of bladder cancer. Expert Rev Clin Immunol. 2015;11(2):265-–79.

Aragon-Ching JB, Nizam A, Henson DE. Carcinomas of the renal pelvis, ureters, and urinary bladder share a carcinogenic field as revealed in epidemiological analysis of tumor registry data. Clinical genitourinary cancer. 2019 Dec 1;17(6):436-42.

Thompson DB, Siref LE, Feloney MP, Hauke RJ, Agrawal DK. Immunological basis in the pathogenesis and treatment of bladder cancer. Expert Rev Clin Immunol. 2015;11(2):265–79.

Lopez-Beltran A, Cimadamore A, Montironi R, Cheng L. Molecular pathology of urothelial carcinoma. Human Pathology. 2021 Jul 1;113:67-83.

Kumar D, Adeniran AJ. Clinicopathological review of micropapillary urothelial carcinoma. Current Oncology Reports. 2022 May;24(5):603-10.

Uribe ML, Marrocco I, Yarden Y. EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance. Cancers. 2021 Jun 1;13(11):2748.

Richters A, Aben KK, Kiemeney LA. The global burden of urinary bladder cancer: an update. World journal of urology. 2020 Aug;38:1895-904.

Kim CH, Kim SH, Park SY, Yoo J, Kim SK, Kim HK. Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation-Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma. Cancer Res Treat. 2015 Oct;47(4):653-60.

Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Medical sciences. 2020 Mar 13;8(1):15.

Abass EC, Jumaah AS, Altoriah KM, Al-Haddad HS, Al-Quzweni A, Alghaszali HR et al.Immunohistochemistry Study Urothelial Carcinoma using Tumor Markers (EGFR, EMA and CD117). Systematic Reviews in Pharmacy. 2020 Apr 1;11(4):223-8.

Leonita Agustin Hambalie L, Anny Setijo Rahaju A, Gondo Mastutik G. The correlation of EMMPRIN and EGFR overexpression toward muscle invasiveness in urothelial carcinoma of bladder. Indian Journal of forensic medicine & toxicology. 2021;15(2):2709-

van der Fels CA, Leliveld A, Buikema H, van den Heuvel MC, de Jong IJ. VEGF, EGFR and PSMA as possible imaging targets of lymph node metastases of urothelial carcinoma of the bladder. BMC urology. 2022 Dec;22(1):1-6.

Hussain ZF, Irfan M, Khan EY, Faridi N, Naqvi H, Khan A, Edhi MM. Prognostic significance of epidermal growth factor receptor (EGFR) over expression in urothelial carcinoma of urinary bladder. BMC urology. 2018 Dec;18(1):1-6.

El-Sheikh P, Shamloula M, Atef A, El-Guindy D. Evaluation of pyruvate kinase M2 (PKM2) and epidermal growth factor receptor (EGFR) expression and their clinicopathologic significance in bladder urothelial carcinoma. International Journal of Cancer and Biomedical Research. 2021 Sep 1;5(3):141-52.

Enache M, Simionescu CE, Stepan A. EGFR and Her2/neu immunoexpression in papillary urothelial bladder carcinomas. Rom J Morphol Embryol. 2013 Jan 1;54(1):137-41.

Ayati A, Moghimi S, Salarinejad S, Safavi M, Pouramiri B, Foroumadi A. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorganic chemistry. 2020 Jun 1;99:103811.

Kumar V, Yadavilli S, Kannan R. A review on RNAi therapy for NSCLC: Opportunities and challenges. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2021 Mar;13(2):e1677.

L. EGFR: an Overview and Mutation on Lung Cancer. Highlights in Science, Engineering and Technology. 2023 Mar 21;36:1046–50.

Additional Files

Published

2024-06-30

Issue

Vol. 36 No. 2 (2024): JOURNAL OF AYUB MEDICAL COLLEGE ABBOTTABAD

Section

ORIGINAL ARTICLE

License

Copyright (c) 2024 Shifa Basharat, Ayesha Sajjad, Faryal Javaid, Maria Khan, Maria Tasneem Khattak, Iqbal Muhammad Khan

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License  CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.

USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.

AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.